Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria

Lacerda, MVG; Llanos-Cuentas, A; Krudsood, S; Lon, C; Saunders, DL; Mohammed, R; Yilma, D; Batista Pereira, D; Espino, FEJ; Mia, RZ; Chuquiyauri, R; Val, F; Casapía, M; Monteiro, WM; Brito, MAM; Costa, MRF; Buathong, N; Noedl, H; Diro, E; Getie, S; Wubie, KM; Abdissa, A; Zeynudin, A; Abebe, C; Tada, MS; Brand, F; Beck, H-P; Angus, B; Duparc, S; Kleim, J-P; Kellam, LM; Rousell, VM; Jones, SW; Hardaker, E; Mohamed, K; Clover, DD; Fletcher, K; Breton, JJ; Ugwuegbulam, CO; Green, JA; Koh, GCKW

Journal article

Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria

Abstract:: Background Treatment of Plasmodium vivax malaria requires the clearing of asexual parasites, but relapse can be prevented only if dormant hypnozoites are cleared from the liver (a treatment termed “radical cure”). Tafenoquine is a single-dose 8-aminoquinoline that has recently been registered for the radical cure of P. vivax.

Methods This multicenter, double-blind, double-dummy, parallel group, randomized, placebo-controlled trial was conducted in Ethiopia, Peru, Brazil, Cambodia, Thailand, and the Philippines. We enrolled 522 patients with microscopically confirmed P. vivax infection (>100 to <100,000 parasites per microliter) and normal glucose-6-phosphate dehydrogenase (G6PD) activity (with normal activity defined as ≥70% of the median value determined at each trial site among 36 healthy male volunteers who were otherwise not involved in the trial). All patients received a 3-day course of chloroquine (total dose of 1500 mg). In addition, patients were assigned to receive a single 300-mg dose of tafenoquine on day 1 or 2 (260 patients), placebo (133 patients), or a 15-mg dose of primaquine once daily for 14 days (129 patients). The primary outcome was the Kaplan–Meier estimated percentage of patients who were free from recurrence at 6 months, defined as P. vivax clearance without recurrent parasitemia.

Results In the intention-to-treat population, the percentage of patients who were free from recurrence at 6 months was 62.4% in the tafenoquine group (95% confidence interval [CI], 54.9 to 69.0), 27.7% in the placebo group (95% CI, 19.6 to 36.6), and 69.6% in the primaquine group (95% CI, 60.2 to 77.1). The hazard ratio for the risk of recurrence was 0.30 (95% CI, 0.22 to 0.40) with tafenoquine as compared with placebo (P<0.001) and 0.26 (95% CI, 0.18 to 0.39) with primaquine as compared with placebo (P<0.001). Tafenoquine was associated with asymptomatic declines in hemoglobin levels, which resolved without intervention.

Conclusions Single-dose tafenoquine resulted in a significantly lower risk of P. vivax recurrence than placebo in patients with phenotypically normal G6PD activity. (Funded by GlaxoSmithKline and Medicines for Malaria Venture; DETECTIVE ClinicalTrials.gov number, NCT01376167. opens in new tab.)

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Lacerda, M. V. G., Llanos-Cuentas, A., Krudsood, S., Lon, C., Saunders, D. L., Mohammed, R., Yilma, D., Batista Pereira, D., Espino, F. E. J., Mia, R. Z., Chuquiyauri, R., Val, F., Casapía, M., Monteiro, W. M., Brito, M. A. M., Costa, M. R. F., Buathong, N., Noedl, H., Diro, E., … Koh, G. C. K. W. (2019). Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. New England Journal of Medicine , 380(3), 215–228.

MLA Style

Lacerda, M. VG, et al. “Single-Dose Tafenoquine to Prevent Relapse of Plasmodium Vivax Malaria.” New England Journal of Medicine , vol. 380, no. 3, Massachusetts Medical Society, 2019, pp. 215–28.

Chicago Style

Lacerda, MVG, A Llanos-Cuentas, S Krudsood, C Lon, DL Saunders, R Mohammed, D Yilma, et al. 2019. “Single-Dose Tafenoquine to Prevent Relapse of Plasmodium Vivax Malaria.” New England Journal of Medicine 380 (3): 215–28.
Share
Print